肾炎舒片联合缬沙坦治疗慢性肾小球肾炎疗效观察及对免疫功能、肾功能的影响

Curative Effect Observe of Shenyanshu Tablets Combined with Valsartan on Chronic Glomerulonephritis and Its Effects on Immunity Function and Kidney Function

目的:观察肾炎舒片联合缬沙坦治疗慢性肾小球肾炎(CGN)的疗效及对免疫功能、肾功能的影响。方法:回顾性分析80例CGN患者,按治疗方法不同分为对照组及治疗组各40例。对照组给予缬沙坦治疗,治疗组在对照组基础上联合肾炎舒片治疗。观察2组临床疗效及不良反应发生情况,比较2组治疗前后肾功能指标[肌酐(Cr)、尿素氮(BUN)、24小时尿蛋白含量(24 h UPro)]、细胞免疫功能(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)值)、炎性因子[白细胞介素-4 (IL-4)、白细胞介素-6 (IL-6),肿瘤坏死因子-α (TNF-α)]指标值的变化。结果:对照组临床疗效总有效率为80.00%,治疗组为95.00%,2组比较,差异有统计学意义(P<0.05)。治疗后,2组CD4^(+)、CD4^(+)/CD8^(+)值均较治疗前升高(P<0.05),CD8^(+)水平均较治疗前下降(P<0.05);治疗组CD4^(+)、CD4^(+)/CD8^(+)值均高于对照组(P<0.05),CD8^(+)水平低于对照组(P<0.05)。治疗后,2组Cr、BUN、24 h Upro水平均较治疗前下降(P<0.05),治疗组Cr、BUN、24 h Upro水平均低于对照组(P<0.05)。治疗后,2组IL-4水平均较治疗前升高(P<0.05),IL-6、TNF-α水平均较治疗前下降(P<0.05);治疗组IL-4水平高于对照组(P<0.05),IL-6、TNF-α水平均低于对照组(P<0.05)。对照组不良反应发生率为10.00%。治疗组不良反应发生率为5.00%,2组比较,差异无统计学意义(P>0.05)。结论:肾炎舒片联合缬沙坦治疗CGN可取得较好疗效,改善肾功能,调节细胞免疫,降低炎症因子,且安全性较高。

Objective:To observe the curative effect of Shenyanshu Tablets combined with Valsartan on chronic glomerulonephritis (CGN) and its effects on immunity function and kidney function.Methods:A retrospective analysis was conducted on 80 patients with CGN and they were divided into the control group and the treatment group according to different treatment methods,with 40 cases in each group.The control group was treated with Valsartan,and the treatment group was additionally treated with Shenyanshu Tablets based on the treatment of the control group.Clinical effects and the incidence of adverse reactions in the two groups were observed.The changes in kidney function indexes,including creatinine (Cr),blood urea nitrogen (BUN) and 24-hour urinary protein content (24 h UPro),cellular immune function indexes,including CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)levels,and serum inflammatory (IL-4,IL-6、TNF-α) indexes were compared between the two groups before and after treatment.Results:The total clinical effective rate was 80.00%in the control group and 95.00%in the treatment group,the difference being significant (P<0.05).After treatment,CD4^(+)and CD4^(+)/CD8^(+)levels in the two groups were increased when compared with those before treatment,and CD8^(+)levels were decreased (P<0.05);the CD4^(+)and CD4^(+)/CD8^(+)levels in the treatment group were higher than those in the control group,and the CD8^(+)level in the treatment group was lower than that in the control group (P<0.05).After treatment,the levels of Cr,BUN,and 24 h UPro in the two groups were decreased when compared with those before treatment (P<0.05),and the above three levels in the treatment group were lower than those in the control group (P<0.05).After treatment,the IL-4 levels in the two groups were increased when compared with those before treatment,and the levels of IL-6 and TNF-α were decreased when compared with those before treatment(P<0.05);the IL-4 level in the treatment group was higher than that in the control group,and the levels of IL-6 and TNF-α in the treatment group were lower than those in the control group (P<0.05).The incidence of adverse reactions was 10.00%in the control group and 5.00%in the treatment group,and there was no significant difference being found between the two groups (P>0.05).Conclusion:The therapy of Shenyanshu Tablets combined with Valsartan has a relatively good curative effect on the treatment of CGN and can improve kidney function,regulate cellular immunity,and reduce inflammatory factors with high safety.